Cardiovascular prevention in HIV patients: Results from a successful intervention program
| Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
|---|---|
| Data(s) |
19/10/2012
19/10/2012
2009
|
| Resumo |
Objectives: To analyze the effect of a prevention program oil the estimated cardiovascular risk calculated by three risk scores. Methods: We prospectively evaluated 87 HIV+ patients with elevated cardiovascular risk estimation. Framirigham (FIRS), PROCAM and National Cholesterol Education Program (ATP-III) were applied. Cardiovascular risk was defined as elevated if >10%. All patients received non-pharmacological (diet, exercise, smoking cessation) and, when appropriate, pharmacological therapy. Results: Mean age was 52 years, 92% were male, 39.1% were smokers, 70.1% had hypertension, 18.4% had diabetes. All patients were under HAART, 56.3% were receiving protease inhibitors (131). After 6 months, intervention was associated to significant changes oil triglycerides (298 242 and 206 +/- 135 mg/dL, p<0.05), total-cholesterol (224 +/- 47 and 189 +/- 38 mg/dL, p<0.001). LDL-cholesterol (129 +/- 44 and 109 +/- 30 mg/dL,p<0.001). Frequencies of patients with elevated cardiac risk before and 6 months after intervention were 92% x 27.6% (p < 0.0001), 80.5% x 50.6% (p < 0.0002), and 25.3% x 14.9% (p = 0.12), for FIRS, ATP III and PROCAM, respectively. Conclusions: An intervention Program focused on reduction of traditional risk factors was able to decrease the frequency of patients with HIV infection and elevated cardiovascular risk estimation. FIRS showed greater sensitivity than the other scores. (C) 2008 Elsevier Ireland Ltd. All rights reserved. |
| Identificador |
ATHEROSCLEROSIS, v.204, n.1, p.229-232, 2009 0021-9150 http://producao.usp.br/handle/BDPI/21838 10.1016/j.atherosclerosis.2008.08.017 |
| Idioma(s) |
eng |
| Publicador |
ELSEVIER IRELAND LTD |
| Relação |
Atherosclerosis |
| Direitos |
restrictedAccess Copyright ELSEVIER IRELAND LTD |
| Palavras-Chave | #HIV #Atherosclerosis #Myocardial infarction #Prevention #Protease inhibitors #MYOCARDIAL-INFARCTION #INFECTED PATIENTS #RISK PROFILE #ADULTS #Peripheral Vascular Disease |
| Tipo |
article original article publishedVersion |